TELA TELA Bio

TELA Bio to Present at the Jefferies Virtual Healthcare Conference

TELA Bio to Present at the Jefferies Virtual Healthcare Conference

MALVERN, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the company will be participating in the upcoming Jefferies Virtual Healthcare Conference.

TELA Bio's management is scheduled to present on Tuesday, June 2, 2020 at 9:00 AM Eastern Daylight Time (EDT). Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company's website at .

About TELA Bio, Inc.

TELA Bio, Inc. is a commercial stage medical technology company focused on designing, developing, and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA's products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA's portfolio is supported by quality, data-driven science and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.

TELA Bio Contact

Stuart Henderson

Vice President, Corporate Development and Investor Relations

TELA Bio, Inc.

484-320-2930

Investor Contact

Greg Chodaczek

347-620-7010 

EN
29/05/2020

Underlying

TELATELA Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TELA Bio

 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio Reports Second Quarter 2025 Financial Results

TELA Bio Reports Second Quarter 2025 Financial Results MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Delivered revenue of $20.2 million in the second quarter 2025, representing growth of 26% over the prior year period and sequential growth of 9% over the first quarter of 2025;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix produ...

August 11, 2025 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 10,200 shares of its common stock to fourteen newly-hired employees, with a grant date of August 5, 2025 (the "Grant Date"). The restricted stock units were granted ...

August 8, 2025 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Co...

TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 45th Annual Growth Conference. TELA’s management is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference at 10:00 am ET on August 13th, 2025. Interested parties can access the live and archived webcast at . About TELA Bio...

July 23, 2025 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio to Announce Second Quarter 2025 Financial Results

TELA Bio to Announce Second Quarter 2025 Financial Results MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2025 financial results on Monday, August 11, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Conference Call and Webcast DetailsInves...

July 21, 2025 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(...

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restricted stock units coveri...

June 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch